Is ADMA Biologics, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for ADMA Biologics, Inc. moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 24, a Price to Book Value of 13.18, and an EV to EBITDA of 30.78. In comparison, its peer Protagonist Therapeutics, Inc. is considered very expensive with a P/E ratio of 67.175, while Rayzebio, Inc. does not qualify for comparison due to negative metrics.
Despite recent struggles, with a year-to-date return of -16.27% compared to the S&P 500's 13.30%, ADMA Biologics has shown impressive long-term performance, with a 3-year return of 433.83% versus the S&P 500's 81.19%. This suggests that while the stock may be facing short-term challenges, its valuation appears justified given its historical performance and current metrics.